<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400946</url>
  </required_header>
  <id_info>
    <org_study_id>05-001 / CDR0000513019</org_study_id>
    <secondary_id>P01CA068484</secondary_id>
    <secondary_id>P30CA006516</secondary_id>
    <secondary_id>DFCI-05001</secondary_id>
    <nct_id>NCT00400946</nct_id>
    <nct_alias>NCT00165165</nct_alias>
  </id_info>
  <brief_title>Treatment of Acute Lymphoblastic Leukemia in Children</brief_title>
  <official_title>Treatment of Acute Lymphoblastic Leukemia in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: L-asparaginase is an important component of treatment for childhood acute
      lymphoblastic leukemia, but is also associated with notable side-effects, including
      hypersensitivity, pancreatitis, and thrombosis. We have previously reported that patients
      with acute lymphoblastic leukemia in whom asparaginase treatment was discontinued because of
      intolerable side-effects had survival outcomes that were inferior to those who received all
      or nearly all of their intended doses. Two bacterial sources of asparaginase exist:
      Escherichia coli (E coli) and Erwinia chrysanthemia (Erwinia). Generally, the E coli-derived
      enzyme has been used as front-line therapy and the Erwinia-derived preparation has been
      reserved for patients who develop hypersensitivity reactions. Pegylated E coli asparaginase
      (PEG-asparaginase) has a longer half-life and is potentially less immunogenic than native E
      coli L-asparaginase, and has been used as the initial asparaginase preparation in some
      pediatric acute lymphoblastic leukemia treatment regimens.

      PURPOSE: Although the pharmacokinetics of each of these asparaginase preparations:
      intravenous PEG-asparaginase (IV-PEG) and intramuscular native E coli L-asparaginase (IM-EC)
      have been well characterized, their relative efficacy and toxicity have not been studied
      extensively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RISK CLASSIFICATION:

      Patients received were classified into initial risk groups defined as:

      High Risk (HR) High risk patients had any of the following features: age 10 years and older,
      a white blood cell count of 50 000 cells per μL or higher, initial spinal fluid sample with
      the presence of lymphoblasts and five or more white blood cells per high power field [Central
      Nervous System (CNS)-3], or a T-cell phenotype.

      Standard Risk (SR) All other patients were classified as standard risk.

      Patients who achieved complete remission (CR) after 32 days of induction therapy defined as a
      marrow specimen with less than 5% marrow blasts and evidence of normal haemopoiesis, absence
      of extramedullary disease, and recovery of peripheral blood counts were randomly assigned in
      a 1:1 ratio to receive IV-PEG or IM-EC. Randomization was stratified by final risk group
      assigned based on end-induction minimal residual disease and cytogenetics as follows:

      Very High Risk (VHR)

      Any initial risk group and any of the following:

        -  MLL gene rearrangement

        -  Hypodiploidy (&lt;45 chromosomes)

        -  B cell-ALL (high) end-induction minimal residual disease (MRD) (&gt;/= 0.001)

      High Risk (HR)

      No VHR features, plus:

      HR initial risk group OR

      SR initial risk group with either of the following:

        -  CNS-2 or CNS-3 on day 18

        -  CNS-2 on day 32 OR

        -  t(9;22) Philadelphia chromosome positive (Ph+ ALL)

      Standard Risk (SR)

      No VHR features, plus:

      SR initial risk group AND

      * CNS-1 on day 18 and 32

      NOTE: CNS-1, Cerebral spinal fluid (CSF) without blasts; CNS-2, CSF with blasts and &lt; 5 WBC
      per high-power field (HPF); CNS-3, CSF with blasts and ≥ 5 WBC per HPF

      THERAPY:

      INDUCTION

        -  Steroid prophase: Patients receive intrathecal (IT) cytarabine on day 1 and
           methylprednisolone IV every 8 hours on days 1-3. Patients then proceed to remission
           induction therapy.

      Patients with CNS leukemia (CNS-2, CNS-3, or traumatic lumbar puncture [LP] with blasts) on
      initial LP receive additional IT cytarabine twice weekly beginning on days 4-6 and continuing
      until cerebrospinal fluid (CSF) is clear, followed by 2 additional doses. Patients with
      cranial nerve palsy but no leukemia blasts in CSF or leukemic eye infiltrates also receive
      additional IT cytarabine as above.

      NOTE: Patients who received steroids within the past 7 days do not receive steroid prophase
      treatment; instead they proceed directly to remission induction therapy according to their
      risk group.

        -  Remission induction therapy (SR patients): Patients receive oral prednisone or
           prednisolone 2-3 times daily OR methylprednisolone IV every 8 hours on days 4-32;
           vincristine IV on days 4, 11, 18, and 25; doxorubicin hydrochloride (DOX) IV over 15
           minutes on days 4 and 5; methotrexate (MTX) IV on day 6; pegasparaginase IV over 1 hour
           on day 7; triple intrathecal therapy (TIT) comprising methotrexate, cytarabine, and
           hydrocortisone on day 18; and IT MTX on day 32.

        -  Remission induction therapy (HR and VHR patients): Patients receive
           prednisone/prednisolone OR methylprednisolone; vincristine; DOX; MTX IV;
           pegasparaginase; TIT; and IT MTX as in the SR group. Patients also receive dexrazoxane
           hydrochloride IV over 15 minutes preceding the DOX infusions on days 4 and 5.

      NOTE: Patients who do not receive steroid prophase treatment also receive IT cytarabine on
      day 4.

      NOTE: Patients who are in CR on day 32 proceed to consolidation I. Patients who do not meet
      protocol definition of CR on day 32 but have no evidence of persistent disease receive
      vincristine IV weekly until CR is achieved. Patients with persistent marrow disease (greater
      than 5% leukemic blasts) and/or persistent extramedullary disease or those who do not achieve
      CR by day 53 are removed from the study.

      NOTE: Patients with Ph+ ALL received imatinib (340 mg/m2 PO maximum 600 mg daily starting day
      18) in combination with HR chemotherapy until they proceeded to stem cell transplant.
      Patients with Ph+ ALL patients did not participate in asparaginase randomization but were
      directly assigned to receive IM-EC during post-induction therapy.

      CONSOLIDATION I

        -  Consolidation I (SR patients): Patients receive vincristine IV and IT MTX on day 1 and
           oral mercaptopurine once daily on days 1-14. Patients also receive high-dose MTX (HDM)
           IV continuously over 24 hours on day 1 and leucovorin calcium IV every 6 hours beginning
           36 hours after the start of the HDM infusion and continuing until MTX levels are
           undetectable. Patients proceed to CNS therapy after day 21.

        -  Consolidation I (HR patients): Patients receive vincristine, IT MTX, and mercaptopurine
           as in the SR group. Patients also receive dexrazoxane hydrochloride IV over 15 minutes
           followed by DOX IV over 15 minutes on day 1 and HDM with leucovorin calcium support as
           in the SR group beginning 8-24 hours after the completion of the DOX infusion. Patients
           proceed to CNS therapy after day 21.

        -  Consolidation I (VHR patients): Patients receive consolidation therapy in 3 stages.

             -  IA: Patients receive vincristine, IT MTX, and mercaptopurine as in the SR group.
                Patients also receive dexrazoxane hydrochloride, DOX, HDM, and leucovorin calcium
                as in the HR group.

             -  IB: Patients receive cyclophosphamide IV over 1 hour and IT MTX on day 22; oral
                mercaptopurine once daily on days 22-35; and cytarabine IV on days 23-26 and 30-33.

             -  IC: Patients receive high-dose cytarabine IV over 3 hours every 12 hours on days 43
                and 44; etoposide IV over 1 hour on days 45-47; and oral dexamethasone twice daily
                on days 43-47. Patients also receive IM-EC weekly beginning on day 48 and
                continuing for up to 30 weeks OR IV-PEG over 1 hour every 2 weeks beginning on day
                48 and continuing for up to 30 weeks. Patients proceed to CNS therapy after day 49.

      KEY RANDOMIZATION: Patients are randomized 1:1 to receive either IV-PEG or IM-EC
      post-induction. Those who achieved a complete remission after induction therapy were assigned
      a final risk group and were eligible to participate in the randomization. The randomization
      was stratified by final risk group.

      NOTE: Ph+ ALL patients did not participate in asparaginase randomization but were directly
      assigned to receive IM-EC during post-induction therapy. Patients who were eligible but
      declined randomization were also directly assigned to receive IM-EC. Patients who developed
      severe pancreatitis (defined as symptoms persisting for &gt;72 h) during induction were not
      eligible for randomization and received no further doses of asparaginase. Patients who had
      hypersensitivity to IV-PEG during induction were also ineligible for randomization, but
      received twice-weekly IM-EC (25 000 IU/m2) during the post-induction treatment phases.

      CNS

        -  CNS therapy (SR patients): Patients receive vincristine IV on day 1; oral mercaptopurine
           once daily on days 1-14; oral dexamethasone twice daily on days 1-5; and TIT twice
           weekly for 2 weeks. Patients also receive IV-PEG OR IM-EC as above beginning on day 1
           and continuing for up to 30 weeks. Patients proceed to consolidation II after day 21.

        -  CNS therapy (HR and VHR patients): Patients receive vincristine, mercaptopurine,
           dexamethasone, and TIT as in the SR group. Patients also receive dexrazoxane
           hydrochloride IV over 15 minutes followed by DOX IV over 15 minutes on day 1. HR
           patients also receive IV-PEG OR IM-EC as above beginning on day 1 and continuing for up
           to 30 weeks. VHR patients continue to receive IV-PEG OR IM-EC as per consolidation I
           treatment. Patients proceed to consolidation II after day 21.

      NOTE: Patients with WBC &gt; 100,000/mm³, T-cell disease, and/or CNS-3 at diagnosis or CNS-2 at
      end of remission induction therapy also undergo cranial radiation therapy daily for 8 or 10
      days.

      CONSOLIDATION II

        -  Consolidation II (SR patients): Patients receive vincristine IV on day 1; oral
           dexamethasone twice daily on days 1-5; and oral mercaptopurine once daily on days 1-14.
           Treatment repeats every 21 days until IV-PEG OR IM-EC is completed. Patients also
           receive MTX IV or IM 1 day after each IV-PEG OR IM-EC dose and TIT every 9 weeks for 6
           doses and then every 18 weeks thereafter.

        -  Consolidation II (HR and VHR patients): Patients receive vincristine, dexamethasone, and
           mercaptopurine as in the SR group. Patients also receive dexrazoxane hydrochloride IV
           over 15 minutes followed by DOX IV over 15 minutes on day 1. Treatment repeats every 21
           days until IV-PEG OR IM-EC is completed. Patients also receive MTX IV or IM as in the SR
           group and TIT every 9 weeks for 6 doses and then every 18 weeks thereafter OR TIT every
           18 weeks.

      CONTINUATION

        -  Continuation therapy: After completion of all consolidation therapy, all patients
           receive vincristine IV on day 1; oral dexamethasone twice daily on days 1-5; oral
           mercaptopurine once daily on days 1-14; and MTX IV or IM on days 1, 8, and 15. Treatment
           repeats every 21 days for up to 24 months (102 weeks) after achieving CR. Patients
           continue to receive TIT as in consolidation II until completion of therapy.

      OBJECTIVES:

      Primary

        -  To determine the relative toxicity of IV PEG asparaginase and IM E.coli asparaginase in
           children with acute lymphoblastic leukemia (ALL)

      Secondary (reported)

        -  To explore the relative efficacy of IV PEG asparaginase and IM E.coliasparaginase

        -  To determine the rate of infections (episodes of bacteremia and disseminated fungal
           infections) during the remission induction phase

        -  To compare trough serum asparaginase enzyme levels, asparagine levels and
           antiasparaginase antibody levels

        -  To evaluate the outcome of patients based upon MRD status after 28 days of multiagent
           chemotherapy within the context of a regimen which intensifies treatment for B-lineage
           patients with MRD levels &gt;0.001 at the end of remission induction (day 32 MRD status
           used)

        -  To evaluate the outcome of patients based upon bone marrow morphology after 14 days of
           multiagent chemotherapy (day 18 marrow morphology status used)

        -  To determine the efficacy of CNS-directed treatments

      Secondary (not reported)

        -  To compare antiasparaginase antibody levels (not available due to problems with the
           assay)

        -  To correlate trough enzyme levels with outcome (toxicity, relapse)

        -  To determine CNS-related toxicity of CNS-directed treatments (data is not mature on late
           neurocognitive impairments in long-term survivors)

        -  To determine the efficacy and CNS-related toxicity (acute and long-term) of the HR
           regimen in which a subset of HR patients (B-lineage, CNS-1 or CNS-2, WBC &lt;100,000/m3)
           are treated with intensive intrathecal chemotherapy and the remainder are treated with
           12 Gy cranial radiation (with intrathecal chemotherapy)

        -  To determine the efficacy and CNS-related toxicity (acute and long-term) of intensive
           intrathecal therapy in SR patients

        -  To determine the prognostic significance of asparaginase antibody formation

        -  To compare randomized treatment groups using health-related quality-of-life analysis
           (connected with a separate protocol 06-373)

        -  To investigate the association of dietary antioxidant micronutrient intake with the rate
           of infections (episodes of bacteremia and disseminated fungal infections) during
           remission induction therapy and the Consolidation IA phase

        -  To determine the relationship of dietary calcium intake with risk for development of
           fractures during the continuation phase of therapy

        -  To evaluate the association of dietary intake of specific nutrients with
           treatment-related toxicities during treatment

        -  To evaluate the outcome of patients based upon MRD status after 14 days of multiagent
           chemotherapy and at various other timepoints while on treatment every 18 weeks after
           achieving complete remission and at the completion of all chemotherapy

        -  To determine the prognostic significance of response to remission induction chemotherapy
           as measured by morphologic and minimal residual disease (MRD) measures within the
           context of DFCI ALL Consortium protocol therapy (data limited due to response outcomes)

        -  To compare rate of infection during remission induction in patients treated with a less
           intensive induction regimen on Protocol 05-01 (low-dose instead of high-dose
           methotrexate) with that of patients treated on prior DFCI ALL Consortium Protocol 00-01
           (induction regimen included high-dose methotrexate)

        -  To determine the concordance of MRD quantification using multi-parameter flow cytometry
           and PCR techniques

        -  To determine the prognostic significance of gene expression programs in childhood ALL
           and identify new targets for specific therapies

        -  To identify clinically relevant gene expression signatures in leukemia cells

        -  To identify gene expression signature in leukemia cells at diagnosis that predicts
           peripheral blood response to the steroid prophase

        -  To identify gene expression changes in leukemia cells induced by steroid treatment

        -  To determine the frequency and type of tyrosine kinase mutations in childhood ALL and
           identify new targets for specific therapies

        -  To explore the potential relationship between abnormal glucose homeostasis during
           therapy and the development of obesity, as well as the potential relationship between
           obesity and the age of pubertal onset (assessed in patients treated at DFCI/CHB only)

        -  To characterize the degree of hyperglycemia and insulin resistance in patients receiving
           therapy for childhood ALL

        -  To characterize the degree of insulin resistance and obesity after the completion of
           therapy for childhood ALL
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asparaginase-Related Toxicity Rate</measure>
    <time_frame>30-week post-induction asparaginase treatment period</time_frame>
    <description>Asparaginase-related toxicity rate is defined as the percentage of patients who experience allergy (all grades), symptomatic pancreatitis (grade 2 or worse), thrombotic or bleeding complications requiring intervention (grade 2 or worse) with treatment attribution of possibly, probably or definite based on CTCAEv3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-Year Disease-Free Survival</measure>
    <time_frame>Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.</time_frame>
    <description>Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as &gt;25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Induction Nadir Serum Asparaginase Activity Level</measure>
    <time_frame>Samples for nadir serum asparaginase activity analyses were obtained before doses administered at weeks 5, 11, 17, 23 and 29 of post-induction asparaginase treatment.</time_frame>
    <description>Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Induction Therapeutic Nadir Serum Asparaginase Activity Rate</measure>
    <time_frame>Samples for nadir serum asparaginase activity analyses were obtained before doses administered at weeks 5, 11, 17, 23 and 29 of post-induction asparaginase treatment.</time_frame>
    <description>Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Post-Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL ever during post-induction therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Infection Toxicity Rate</measure>
    <time_frame>Assessed daily during remission induction days 4-32.</time_frame>
    <description>Infection toxicity rate is defined as the percentage of patients who experience bacterial or fungal infection of grade 3 or higher with treatment attribution of possibly, probably or definite based on CTCAEv3 during remission induction phase of combination chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Serum Asparaginase Activity Level</measure>
    <time_frame>Samples for serum asparaginase activity analyses were obtained days 4, 11, 18 and 25 post one-dose of IV-PEG on day 7 of the induction phase.</time_frame>
    <description>Serum asparaginase activity (NSAA) levels were estimated based on established methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Therapeutic Nadir Serum Asparaginase Activity Rate</measure>
    <time_frame>Samples for serum asparaginase activity analyses were obtained days 4, 11, 18 and 25 post one-dose of IV-PEG on day 7 of the induction phase.</time_frame>
    <description>Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL at a given timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-Year Disease-Free Survival by MRD Day 32 Status</measure>
    <time_frame>Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.</time_frame>
    <description>Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as &gt;25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-Year Disease-Free Survival by Bone Marrow Day 18 Status</measure>
    <time_frame>Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.</time_frame>
    <description>Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as &gt;25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year Disease-Free Survival by CNS Directed Treatment Group</measure>
    <time_frame>Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.</time_frame>
    <description>Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as &gt;25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">800</enrollment>
  <condition>Drug/Agent Toxicity by Tissue/Organ</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm were randomized to intramuscular native E coli L-asparaginase 25 000 IU/m2 weekly for 30 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm were randomized to intravenous PEG-asparaginase 2500 IU/m2 every 2 weeks for 15 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asparaginase</intervention_name>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexrazoxane hydrochloride</intervention_name>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>therapeutic hydrocortisone</intervention_name>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Intramuscular native E coli L-asparaginase (IM-EC)</arm_group_label>
    <arm_group_label>Intravenous PEG-asparaginase (IV-PEG)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of acute lymphoblastic leukemia (ALL)

               -  No known mature B-cell ALL, defined by the presence of any of the following:

                    -  Surface immunoglobulin

                    -  L3 morphology

                    -  t(8;14)(q24;q32)

                    -  t(8;22)

                    -  t(2;8)

               -  T-cell surface markers and t(8;14)(q24;q11) allowed

          -  No secondary ALL

        PATIENT CHARACTERISTICS:

          -  No known HIV positivity

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  No prior therapy except steroids of ≤ 1 week in duration and/or emergent radiation
             therapy to the mediastinum

               -  Patients treated with steroids within the past 7 days will not receive steroid
                  prophase during study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lewis B. Silverman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center at Albert Einstein College of Medicine</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hasbro Children's Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INOVA Fairfax Hospital</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche du Centre Hospitalier de l'Universite Laval</name>
      <address>
        <city>Sainte Foy</city>
        <state>Quebec</state>
        <zip>GIV 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jorge Children's Hospital</name>
      <address>
        <city>Santurce</city>
        <zip>00912</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Laverdière C, Michon B, Schorin M, Schwartz CL, O'Brien JE, Cohen HJ, Sallan SE. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010 Feb 18;115(7):1351-3. doi: 10.1182/blood-2009-09-245951. Epub 2009 Dec 10.</citation>
    <PMID>20007809</PMID>
  </results_reference>
  <results_reference>
    <citation>Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1677-90. doi: 10.1016/S1470-2045(15)00363-0. Epub 2015 Nov 6.</citation>
    <PMID>26549586</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2006</study_first_submitted>
  <study_first_submitted_qc>November 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2006</study_first_posted>
  <results_first_submitted>January 17, 2017</results_first_submitted>
  <results_first_submitted_qc>May 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Lewis B. Silverman, M.D.</investigator_full_name>
    <investigator_title>Silverman, Lewis MD</investigator_title>
  </responsible_party>
  <keyword>drug/agent toxicity by tissue/organ</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>L1 childhood acute lymphoblastic leukemia</keyword>
  <keyword>L2 childhood acute lymphoblastic leukemia</keyword>
  <keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Razoxane</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients enrolled from April 22, 2005 to Dec 13, 2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intramuscular Native E Coli L-asparaginase (IM-EC)</title>
          <description>Patients in this arm were randomized to intramuscular native E coli L-asparaginase 25 000 IU/m2 weekly for 30 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
        </group>
        <group group_id="P2">
          <title>Intravenous PEG-asparaginase (IV-PEG)</title>
          <description>Patients in this arm were randomized to intravenous PEG-asparaginase 2500 IU/m2 every 2 weeks for 15 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
        </group>
        <group group_id="P3">
          <title>IM-EC [Directly Assigned]</title>
          <description>Ph+ ALL patients did not participate in asparaginase randomization but were directly assigned to receive intramuscular E coli L-asparaginase during post-induction therapy. Patients who were eligible but declined randomization were also directly assigned to receive intramuscular E coli L-asparaginase.</description>
        </group>
        <group group_id="P4">
          <title>Ineligible for Randomization</title>
          <description>All patients received a single dose of intravenous PEG-asparaginase 2500 IU/m2 during multi-agent induction. Patients who did not achieve complete remission and were not assigned a final risk group by the end of the induction phase of treatment were not eligible for randomization. Patients who developed severe pancreatitis (defined as symptoms persisting for &gt;72 h) during induction were not eligible for randomization and received no further doses of asparaginase. Patients who had hypersensitivity to intravenous PEG-asparaginase during induction were also ineligible for randomization, but received twice-weekly IM-EC (25 000 IU/m2) during the post-induction treatment phases.</description>
        </group>
        <group group_id="P5">
          <title>Expansion Cohort</title>
          <description>Patients were enrolled in an expansion cohort to determine the prognostic significance of response to remission induction chemotherapy as measured by morphologic and minimal residual disease (MRD), and to further evaluate the efficacy of patients by final risk classification.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="232"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Evaluable for CNS Directed-Treatment</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="232"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Evaluable for Day 18 Marrow Morphology</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="161"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Evaluable for Day 32 MRD</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="167"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible and Treated</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="232"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="46"/>
                <participants group_id="P5" count="243"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
                <participants group_id="P2" count="221"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="47"/>
                <participants group_id="P5" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Induction Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Induction Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Remission Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapse</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transplant in CR1</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis dataset is comprised of all enrolled patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Intramuscular Native E Coli L-asparaginase (IM-EC)</title>
          <description>Patients in this arm were randomized to intramuscular native E coli L-asparaginase 25 000 IU/m2 weekly for 30 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
        </group>
        <group group_id="B2">
          <title>Intravenous PEG-asparaginase (IV-PEG)</title>
          <description>Patients in this arm were randomized to intravenous PEG-asparaginase 2500 IU/m2 every 2 weeks for 15 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
        </group>
        <group group_id="B3">
          <title>IM-EC [Directly Assigned]</title>
          <description>Ph+ ALL patients did not participate in asparaginase randomization but were directly assigned to receive intramuscular E coli L-asparaginase during post-induction therapy. Patients who were eligible but declined randomization were also directly assigned to receive intramuscular E coli L-asparaginase.</description>
        </group>
        <group group_id="B4">
          <title>Ineligible for Randomization</title>
          <description>All patients received a single dose of intravenous PEG-asparaginase 2500 IU/m2 during multi-agent induction. Patients who did not achieve complete remission and were not assigned a final risk group by the end of the induction phase of treatment were not eligible for randomization. Patients who developed severe pancreatitis (defined as symptoms persisting for &gt;72 h) during induction were not eligible for randomization and received no further doses of asparaginase. Patients who had hypersensitivity to intravenous PEG-asparaginase during induction were also ineligible for randomization, but received twice-weekly IM-EC (25 000 IU/m2) during the post-induction treatment phases.</description>
        </group>
        <group group_id="B5">
          <title>Expansion Cohort</title>
          <description>Patients were enrolled in an expansion cohort to determine the prognostic significance of response to remission induction chemotherapy as measured by morphologic and minimal residual disease (MRD), and to further evaluate the efficacy of patients by final risk classification.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="231"/>
            <count group_id="B2" value="232"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="244"/>
            <count group_id="B6" value="800"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="244"/>
                    <measurement group_id="B6" value="800"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="107"/>
                    <measurement group_id="B6" value="357"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="137"/>
                    <measurement group_id="B6" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="180"/>
                    <measurement group_id="B6" value="584"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 10 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="196"/>
                    <measurement group_id="B6" value="598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 10 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Asparaginase-Related Toxicity Rate</title>
        <description>Asparaginase-related toxicity rate is defined as the percentage of patients who experience allergy (all grades), symptomatic pancreatitis (grade 2 or worse), thrombotic or bleeding complications requiring intervention (grade 2 or worse) with treatment attribution of possibly, probably or definite based on CTCAEv3.</description>
        <time_frame>30-week post-induction asparaginase treatment period</time_frame>
        <population>The analysis dataset is comprised of all randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Intramuscular Native E Coli L-asparaginase (IM-EC)</title>
            <description>Patients in this arm were randomized to intramuscular native E coli L-asparaginase 25 000 IU/m2 weekly for 30 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous PEG-asparaginase (IV-PEG)</title>
            <description>Patients in this arm were randomized to intravenous PEG-asparaginase 2500 IU/m2 every 2 weeks for 15 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
          </group>
        </group_list>
        <measure>
          <title>Asparaginase-Related Toxicity Rate</title>
          <description>Asparaginase-related toxicity rate is defined as the percentage of patients who experience allergy (all grades), symptomatic pancreatitis (grade 2 or worse), thrombotic or bleeding complications requiring intervention (grade 2 or worse) with treatment attribution of possibly, probably or definite based on CTCAEv3.</description>
          <population>The analysis dataset is comprised of all randomized patients.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="20" upper_limit="32"/>
                    <measurement group_id="O2" value="28" lower_limit="22" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.60</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-Year Disease-Free Survival</title>
        <description>Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as &gt;25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.</description>
        <time_frame>Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.</time_frame>
        <population>The analysis dataset is comprised of all randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Intramuscular Native E Coli L-asparaginase (IM-EC)</title>
            <description>Patients in this arm were randomized to intramuscular native E coli L-asparaginase 25 000 IU/m2 weekly for 30 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous PEG-asparaginase (IV-PEG)</title>
            <description>Patients in this arm were randomized to intravenous PEG-asparaginase 2500 IU/m2 every 2 weeks for 15 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
          </group>
        </group_list>
        <measure>
          <title>5-Year Disease-Free Survival</title>
          <description>Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as &gt;25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.</description>
          <population>The analysis dataset is comprised of all randomized patients.</population>
          <units>probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".89" lower_limit=".85" upper_limit=".93"/>
                    <measurement group_id="O2" value=".90" lower_limit=".86" upper_limit=".94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Induction Nadir Serum Asparaginase Activity Level</title>
        <description>Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods.</description>
        <time_frame>Samples for nadir serum asparaginase activity analyses were obtained before doses administered at weeks 5, 11, 17, 23 and 29 of post-induction asparaginase treatment.</time_frame>
        <population>The analysis dataset is comprised of all randomized patients who consented to research studies with an evaluable sample for analysis of serum asparaginase activity at the respective post-induction assessment timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Intramuscular Native E Coli L-asparaginase (IM-EC)</title>
            <description>Patients in this arm were randomized to intramuscular native E coli L-asparaginase 25 000 IU/m2 weekly for 30 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous PEG-asparaginase (IV-PEG)</title>
            <description>Patients in this arm were randomized to intravenous PEG-asparaginase 2500 IU/m2 every 2 weeks for 15 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Induction Nadir Serum Asparaginase Activity Level</title>
          <description>Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods.</description>
          <population>The analysis dataset is comprised of all randomized patients who consented to research studies with an evaluable sample for analysis of serum asparaginase activity at the respective post-induction assessment timepoints.</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 5 NSAA Level</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.129" spread="0.108"/>
                    <measurement group_id="O2" value="0.726" spread="0.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11 NSAA Level</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.143" spread="0.131"/>
                    <measurement group_id="O2" value="0.773" spread="0.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17 NSAA Level</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.159" spread="0.161"/>
                    <measurement group_id="O2" value="0.787" spread="0.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 23 NSAA Level</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.180" spread="0.261"/>
                    <measurement group_id="O2" value="0.757" spread="0.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 29 NSAA Level</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.123" spread="0.102"/>
                    <measurement group_id="O2" value="0.806" spread="0.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Induction Therapeutic Nadir Serum Asparaginase Activity Rate</title>
        <description>Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Post-Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL ever during post-induction therapy.</description>
        <time_frame>Samples for nadir serum asparaginase activity analyses were obtained before doses administered at weeks 5, 11, 17, 23 and 29 of post-induction asparaginase treatment.</time_frame>
        <population>The analysis dataset is comprised of all randomized patients who consented to research studies with a one post-induction evaluable sample for analysis of serum asparaginase activity.</population>
        <group_list>
          <group group_id="O1">
            <title>Intramuscular Native E Coli L-asparaginase (IM-EC)</title>
            <description>Patients in this arm were randomized to intramuscular native E coli L-asparaginase 25 000 IU/m2 weekly for 30 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous PEG-asparaginase (IV-PEG)</title>
            <description>Patients in this arm were randomized to intravenous PEG-asparaginase 2500 IU/m2 every 2 weeks for 15 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Induction Therapeutic Nadir Serum Asparaginase Activity Rate</title>
          <description>Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Post-Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL ever during post-induction therapy.</description>
          <population>The analysis dataset is comprised of all randomized patients who consented to research studies with a one post-induction evaluable sample for analysis of serum asparaginase activity.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="63" upper_limit="77"/>
                    <measurement group_id="O2" value="99" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Infection Toxicity Rate</title>
        <description>Infection toxicity rate is defined as the percentage of patients who experience bacterial or fungal infection of grade 3 or higher with treatment attribution of possibly, probably or definite based on CTCAEv3 during remission induction phase of combination chemotherapy.</description>
        <time_frame>Assessed daily during remission induction days 4-32.</time_frame>
        <population>The analysis dataset is comprised of eligible and treated patients. This excludes the 6 enrolled but ineligible patients. Rates in this overall study cohort will be compared against historical controls (in particular patients treated with a more intensive induction regimen).</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. All patients received a single dose of intravenous PEG-asparaginase 2500 IU/m2 during multi-agent induction. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization wherein patients received either E. coli L-asparaginase or peg-asparaginase. Standard risk and high-risk patients began post-induction randomized asparaginase therapy at the start of the CNS phase, whereas very high-risk patients began asparaginase therapy on day 8 of consolidation phase IC. Patients who did not achieve complete remission by the end of the induction phase were not eligible for randomization, were removed from protocol treatment, and received alternative therapy according to the discretion of their treating physician. Further details are provided in the study description section.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Infection Toxicity Rate</title>
          <description>Infection toxicity rate is defined as the percentage of patients who experience bacterial or fungal infection of grade 3 or higher with treatment attribution of possibly, probably or definite based on CTCAEv3 during remission induction phase of combination chemotherapy.</description>
          <population>The analysis dataset is comprised of eligible and treated patients. This excludes the 6 enrolled but ineligible patients. Rates in this overall study cohort will be compared against historical controls (in particular patients treated with a more intensive induction regimen).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="794"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="23" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Serum Asparaginase Activity Level</title>
        <description>Serum asparaginase activity (NSAA) levels were estimated based on established methods.</description>
        <time_frame>Samples for serum asparaginase activity analyses were obtained days 4, 11, 18 and 25 post one-dose of IV-PEG on day 7 of the induction phase.</time_frame>
        <population>The analysis dataset is comprised of all randomized patients who consented to research studies with an evaluable sample for analysis of serum asparaginase activity at the respective induction assessment timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. All patients received a single dose of intravenous PEG-asparaginase 2500 IU/m2 during multi-agent induction. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization wherein patients received either E. coli L-asparaginase or peg-asparaginase. Standard risk and high-risk patients began post-induction randomized asparaginase therapy at the start of the CNS phase, whereas very high-risk patients began asparaginase therapy on day 8 of consolidation phase IC. Patients who did not achieve complete remission by the end of the induction phase were not eligible for randomization, were removed from protocol treatment, and received alternative therapy according to the discretion of their treating physician. Further details are provided in the study description section.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Serum Asparaginase Activity Level</title>
          <description>Serum asparaginase activity (NSAA) levels were estimated based on established methods.</description>
          <population>The analysis dataset is comprised of all randomized patients who consented to research studies with an evaluable sample for analysis of serum asparaginase activity at the respective induction assessment timepoints.</population>
          <units>IU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="794"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4 NSAA Level</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".694" lower_limit=".556" upper_limit=".868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 NSAA Level</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".505" lower_limit=".306" upper_limit=".632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 18 NSAA Level</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".211" lower_limit=".150" upper_limit=".259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 25 NSAA Level</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".048" lower_limit=".025" upper_limit=".076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Therapeutic Nadir Serum Asparaginase Activity Rate</title>
        <description>Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL at a given timepoint.</description>
        <time_frame>Samples for serum asparaginase activity analyses were obtained days 4, 11, 18 and 25 post one-dose of IV-PEG on day 7 of the induction phase.</time_frame>
        <population>The analysis dataset is comprised of all randomized patients who consented to research studies with an evaluable sample for analysis of serum asparaginase activity at the respective induction assessment timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. All patients received a single dose of intravenous PEG-asparaginase 2500 IU/m2 during multi-agent induction. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization wherein patients received either E. coli L-asparaginase or peg-asparaginase. Standard risk and high-risk patients began post-induction randomized asparaginase therapy at the start of the CNS phase, whereas very high-risk patients began asparaginase therapy on day 8 of consolidation phase IC. Patients who did not achieve complete remission by the end of the induction phase were not eligible for randomization, were removed from protocol treatment, and received alternative therapy according to the discretion of their treating physician. Further details are provided in the study description section.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Therapeutic Nadir Serum Asparaginase Activity Rate</title>
          <description>Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL at a given timepoint.</description>
          <population>The analysis dataset is comprised of all randomized patients who consented to research studies with an evaluable sample for analysis of serum asparaginase activity at the respective induction assessment timepoints.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="794"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4 NSAA Rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 NSAA Rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 18 NSAA Rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 25 NSAA Rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-Year Disease-Free Survival by MRD Day 32 Status</title>
        <description>Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as &gt;25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.</description>
        <time_frame>Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.</time_frame>
        <population>The analysis dataset is comprised of B cell ALL patients who achieved an induction complete remission with an evaluable sample at day 32 for analysis of MRD.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Day 32 MRD Level</title>
            <description>Low end-induction (day 32) minimal residual disease (MRD) evaluated was defined as &lt;0.001. This MRD classification was one component of determining final risk classification. Peripheral blood samples were collected for evaluation of MRD using PCR methods.</description>
          </group>
          <group group_id="O2">
            <title>High Day 32 MRD Level</title>
            <description>High end-induction (day 32) minimal residual disease (MRD) evaluated was defined as &gt;/=0.001. This MRD classification was one component of determining final risk classification. Peripheral blood samples were collected for evaluation of MRD using PCR methods</description>
          </group>
        </group_list>
        <measure>
          <title>5-Year Disease-Free Survival by MRD Day 32 Status</title>
          <description>Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as &gt;25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.</description>
          <population>The analysis dataset is comprised of B cell ALL patients who achieved an induction complete remission with an evaluable sample at day 32 for analysis of MRD.</population>
          <units>probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".79" lower_limit=".60" upper_limit=".86"/>
                    <measurement group_id="O2" value=".90" lower_limit=".87" upper_limit=".93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-Year Disease-Free Survival by Bone Marrow Day 18 Status</title>
        <description>Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as &gt;25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.</description>
        <time_frame>Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.</time_frame>
        <population>The analysis dataset is comprised of patients who achieved an induction complete remission with an evaluable sample at day 18 (optional submission) for analysis of marrow morphology.</population>
        <group_list>
          <group group_id="O1">
            <title>M1 Day 18 Bone Marrow Status</title>
            <description>M1 marrow morphology at day 18 was defined as &lt;5% blasts.</description>
          </group>
          <group group_id="O2">
            <title>M2/M3 Day 18 Bone Marrow Status</title>
            <description>M2 marrow morphology at day 18 was defined as 5-24% blasts. M3 marrow morphology at day 18 was defined as &gt;25% blasts.</description>
          </group>
          <group group_id="O3">
            <title>Hypocellular Day 18 Bone Marrow Status</title>
            <description>Hypocellular marrow morphology at day 18 was defined as empty blasts.</description>
          </group>
        </group_list>
        <measure>
          <title>5-Year Disease-Free Survival by Bone Marrow Day 18 Status</title>
          <description>Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as &gt;25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.</description>
          <population>The analysis dataset is comprised of patients who achieved an induction complete remission with an evaluable sample at day 18 (optional submission) for analysis of marrow morphology.</population>
          <units>probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".89" lower_limit=".85" upper_limit=".92"/>
                    <measurement group_id="O2" value=".78" lower_limit=".54" upper_limit=".90"/>
                    <measurement group_id="O3" value=".88" lower_limit=".82" upper_limit=".92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-year Disease-Free Survival by CNS Directed Treatment Group</title>
        <description>Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as &gt;25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.</description>
        <time_frame>Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.</time_frame>
        <population>The analysis dataset is comprised of patients who achieved an induction complete remission with an evaluable sample at diagnosis for analysis of CNS-directed therapy .</population>
        <group_list>
          <group group_id="O1">
            <title>CNS-1</title>
            <description>CNS-1: no blast cells in cytospin, regardless of cerebrospinal fluid (CSF) count</description>
          </group>
          <group group_id="O2">
            <title>CNS-2</title>
            <description>CNS-2: 5 or fewer WBC on CSF cell count, with blasts on cytospin</description>
          </group>
          <group group_id="O3">
            <title>CNS-3</title>
            <description>CNS-3: more than 5 WBC on CSF cell count, with blasts on cytospin</description>
          </group>
          <group group_id="O4">
            <title>Traumatic Tap With Blasts</title>
            <description>Traumatic Tap with Blasts: with blast cells and &gt;100 RBCs on a wet prep</description>
          </group>
          <group group_id="O5">
            <title>Traumatic Tap Without Blasts</title>
            <description>Traumatic Tap without Blasts: without blast cells and &gt;100 RBCs on a wet prep</description>
          </group>
        </group_list>
        <measure>
          <title>5-year Disease-Free Survival by CNS Directed Treatment Group</title>
          <description>Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as &gt;25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI.</description>
          <population>The analysis dataset is comprised of patients who achieved an induction complete remission with an evaluable sample at diagnosis for analysis of CNS-directed therapy .</population>
          <units>probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="579"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".89" lower_limit=".87" upper_limit=".92"/>
                    <measurement group_id="O2" value=".89" lower_limit=".82" upper_limit=".94"/>
                    <measurement group_id="O3" value="1.00">NA-not applicable since all patients were disease-free at 5 years.</measurement>
                    <measurement group_id="O4" value=".84" lower_limit=".67" upper_limit=".93"/>
                    <measurement group_id="O5" value=".87" lower_limit=".58" upper_limit=".97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AE) were continuously monitored and reported every 3 months during treatment except bony events (avascular necrosis and fracture) which were followed up to 10 years. Treatment duration for this study cohort was a median (range) of 757 days (1-881 days). Data is reported for the entire study cohort (n=794) and comparing randomized arms (n=231/n=232), other non-randomized reporting groups are not reported separately since the intent was not to compare rates between these groups.</time_frame>
      <desc>Reporting included (trt-related, all grades [G] unless specified): asparaginase-related allergy, symptomatic pancreatitis (&gt;G1), thrombotic or bleeding complications requiring intervention (&gt;G1), infections (&gt;G2), symptomatic osteonecrosis (&gt;G1), bone fractures and seizures. All other G4-5 AEs were also collected, excl G4 hematological and G4 asymptomatic elevated aminotransferases. Maximum grade toxicity by type was calculated with serious and other AEs defined as G3-5 and G1-2, respectively.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intramuscular Native E Coli L-asparaginase (IM-EC)</title>
          <description>Patients in this arm were randomized to intramuscular native E coli L-asparaginase 25 000 IU/m2 weekly for 30 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
        </group>
        <group group_id="E2">
          <title>Intravenous PEG-asparaginase (IV-PEG)</title>
          <description>Patients in this arm were randomized to intravenous PEG-asparaginase 2500 IU/m2 every 2 weeks for 15 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.</description>
        </group>
        <group group_id="E3">
          <title>Overall</title>
          <description>Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. All patients received a single dose of intravenous PEG-asparaginase 2500 IU/m2 during multi-agent induction. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization wherein patients received either E. coli L-asparaginase or peg-asparaginase. Standard risk and high-risk patients began post-induction randomized asparaginase therapy at the start of the CNS phase, whereas very high-risk patients began asparaginase therapy on day 8 of consolidation phase IC. Patients who did not achieve complete remission by the end of the induction phase were not eligible for randomization, were removed from protocol treatment, and received alternative therapy according to the discretion of their treating physician. Further details are provided in the study description section.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="574" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematologic-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Cardiac-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cecum/appendix- hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Necrosis- pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Oral cavity- pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Perforation- stomach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Ulcer- anus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Ulcer- duodenum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Ulcer- esophagus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Ulcer- gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Varices (esophageal)- hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Duodenum- hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Lower GI- hemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Oral gums- pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Perforation- small bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Upper GI- hemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Abdomen- pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom) oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Typhlitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis by exam- oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death - multiorgan failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Death - sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Edema limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Fever w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Extremity-lower (gait/walking)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Gr0-2 neut- bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- bronchus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- cervix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- dental-tooth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- middle ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- muscle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- soft tissue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- spleen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- brain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- brain + spinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- dental-tooth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- eye NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- lens</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- lip/perioral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- paranasal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- pleura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- sinus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- spinal cord</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- spleen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- trachea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC lymphatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC meninges</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC ungual (nails)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- catheter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- eye NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- peritoneal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- wound</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- anal/perianal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- kidney</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- meninges</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- middle ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- peritoneal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- catheter relate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- upper airway</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- lung</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- skin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Colitis- infectious (e.g. C.diff)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Opportunistic infection lymphopenia&gt;=gr1</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr 0-2 neut- blood</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr 3-4 neut- blood</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="234" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intra-op injury Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Intra-op injury Pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Surgical hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Wound - non-infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ADH secretion abnormality (eg SIADH)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Coagulation-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Fibrinogen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>GGT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>AST- SGOT</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>ALT- SGPT</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Iron overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Urinary electrolyte wasting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back- pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Joint- pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Muscular/skeletal hypoplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Nonneuropathic lower extr muscle weak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Soft tissue necrosis- extremity lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Bone- pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Extremity-limb- pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Osteonecrosis (avascular necrosis)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Neurologic-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>CNS- hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Personality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney- pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Obstruction-ureteral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Perforation- appendix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic- pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchopulmonary- hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Lung- hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>(ARDS)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Skin-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vascular leak syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Chyle or lymph leakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Peripheral arterial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Vascular access-Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis- middle ear (non-infectious)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom) anus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Oral cavity- pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Perforation- stomach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Ulcer- anus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Typhlitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom) oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis by exam- oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest/thoracic pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Extremity-lower (gait/walking)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Fever w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Gr0-2 neut- bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- bronchus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- external ear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- eye NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- kidney</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- lymphatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- meninges</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- bronchus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- catheter relate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- eye NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- larynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- middle ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- peritoneal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- pharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut- wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC catheter related</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC ungual (nails)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- conjunctiva</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- middle ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- mucosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- ungual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- upper airway</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- nose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- sinus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection w/ gr 3-4 neut- blood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection-other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Colitis- infectious (e.g. C.diff)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Opportunistic infection lymphopenia&gt;=gr1</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Infection Gr 0-2 neut- blood</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chemoradiation dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>ALT- SGPT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>AST- SGOT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle- pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft tissue-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Nonneuropathic lower extr muscle weak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Back- pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Joint- pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Bone- pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Extremity-limb- pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Osteonecrosis (avascular necrosis)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>CNS- hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Personality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Skin-other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Vascular access-Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="794"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="794"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lewis B. Silverman, MD</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617.632.6191</phone>
      <email>Lewis_Silverman@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

